Risperidone
Risperidone is an atypical antipsychotic used for schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder. It is a potent D2 and 5-HT2A receptor antagonist and has a higher risk of EPS and prolactin elevation than some other atypicals.
Uses & FDA Indications
Risperidone was introduced in 1994 as one of the first second-generation (atypical) antipsychotics, developed to improve upon first-generation agents by reducing extrapyramidal side effects while maintaining antipsychotic efficacy. It remains one of the most widely prescribed antipsychotics globally and is available both orally and as long-acting injectable (LAI) formulations — critical for patients with chronic schizophrenia where adherence to daily oral medication is a clinical challenge.
FDA-approved indications include: schizophrenia (adults and adolescents ages 13–17), acute treatment of manic or mixed episodes associated with bipolar I disorder (adults and children ages 10–17, as monotherapy or adjunct to lithium or valproate), and irritability associated with autism spectrum disorder (ASD) in children and adolescents ages 5–16. The autism-related irritability indication — targeting aggressive behavior, self-injuriousness, tantrums, and rapidly cycling mood states — makes risperidone one of only two FDA-approved medications for this pediatric population (the other is aripiprazole).
Off-label uses are broad and include: Tourette's disorder, treatment-resistant depression as an adjunct, delirium management in inpatient settings, and behavioral symptoms of dementia (though this is strongly cautioned by a black box warning regarding mortality risk in elderly patients). Risperidone is also used off-label for various pediatric behavioral conditions, though the long-term risk-benefit profile in developing patients requires careful evaluation.
How It Works
Risperidone is a benzisoxazole derivative that acts as an antagonist at dopamine D2 receptors and serotonin 5-HT2A receptors — the core pharmacological mechanism shared by all atypical antipsychotics. D2 blockade in the mesolimbic pathway reduces dopaminergic hyperactivity underlying positive psychotic symptoms (hallucinations, delusions, disorganized thought). Concurrent 5-HT2A blockade — particularly in the mesocortical pathway — is thought to moderate the D2 blockade effect, reducing EPS tendency relative to first-generation agents and potentially improving negative symptoms and cognitive function.
Among atypical antipsychotics, risperidone has relatively high D2 receptor affinity — approaching that of first-generation agents at higher doses. This characteristic is the primary reason risperidone produces more extrapyramidal side effects and more prolactin elevation than most other atypical antipsychotics. Risperidone also blocks alpha-1 adrenergic receptors (contributing to orthostatic hypotension and dizziness) and histamine H1 receptors (contributing to sedation and weight gain). It has minimal muscarinic (anticholinergic) activity compared to many other antipsychotics.
Risperidone's active metabolite, paliperidone (9-hydroxyrisperidone), is itself an FDA-approved antipsychotic marketed as Invega. The pharmacological activity of risperidone is the combined effect of the parent compound and paliperidone. Patients who are CYP2D6 poor metabolizers accumulate more risperidone relative to paliperidone; extensive metabolizers convert more rapidly to the paliperidone form. This pharmacokinetic variability is clinically relevant when considering drug interactions that affect CYP2D6 activity.
BLACK BOX WARNING — ELDERLY PATIENTS WITH DEMENTIA: Atypical antipsychotics including risperidone are associated with increased risk of death in elderly patients treated for dementia-related psychosis. Causes of death were most commonly cardiovascular (heart failure, sudden death) or infectious (pneumonia). Risperidone is not approved for the treatment of dementia-related psychosis. This warning applies to all antipsychotics in this population.
Side Effects
Common
- Extrapyramidal symptoms (EPS) — risperidone has higher EPS risk than most atypical antipsychotics, particularly at higher doses. Includes parkinsonism (tremor, rigidity, bradykinesia), akathisia (motor restlessness — often distressing and a driver of non-adherence), and dystonia (involuntary sustained muscle contractions). Risk is dose-dependent.
- Hyperprolactinemia — risperidone causes greater prolactin elevation than any other commonly used atypical antipsychotic, often 5–10 times the upper limit of normal. Clinical consequences include: menstrual irregularities and amenorrhea, sexual dysfunction (decreased libido, erectile dysfunction), gynecomastia (breast tissue growth in men), galactorrhea (breast milk production outside of pregnancy), and reduced bone mineral density with chronic elevation.
- Weight gain — moderate; more than aripiprazole or ziprasidone, less than olanzapine or clozapine. More pronounced in children and adolescents.
- Sedation and fatigue — particularly at treatment initiation and with higher doses; related to H1 and alpha-1 blockade.
- Orthostatic hypotension and dizziness — alpha-1 adrenergic blockade causes blood pressure to drop on standing, particularly with initial dosing or rapid titration. Fall risk in elderly patients.
- Nasal congestion, rhinitis — via alpha-1 blockade.
- Anxiety, agitation, insomnia — particularly early in treatment.
Serious
- Tardive dyskinesia (TD) — involuntary repetitive movements (lip-smacking, tongue protrusion, facial grimacing, limb movements) that may become irreversible after prolonged antipsychotic use. Risk is lower than with first-generation agents but is higher with risperidone than with quetiapine or clozapine among atypicals. Requires regular monitoring with structured assessments (AIMS scale).
- Neuroleptic malignant syndrome (NMS) — rare but potentially fatal medical emergency. Characterized by hyperthermia, severe muscle rigidity, autonomic instability (diaphoresis, tachycardia, blood pressure fluctuation), and altered consciousness. Requires immediate antipsychotic discontinuation and emergency supportive care.
- QT prolongation — dose-dependent; increases risk of serious ventricular arrhythmias (torsades de pointes), particularly when combined with other QT-prolonging agents or in patients with electrolyte abnormalities or baseline cardiac disease.
- Metabolic syndrome — hyperglycemia, new-onset type 2 diabetes, dyslipidemia. Baseline and ongoing metabolic monitoring is a standard of care requirement for all atypical antipsychotics.
- Cerebrovascular events in elderly patients — clinical trials in elderly patients with dementia showed increased incidence of stroke and transient ischemic attack.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| CYP2D6 Inhibitors (fluoxetine, paroxetine, bupropion) | Inhibit risperidone metabolism via CYP2D6, increasing plasma levels of risperidone and potentially raising EPS, prolactin effects, and QT risk. The effect is especially pronounced with paroxetine and fluoxetine. | Moderate-High — monitor for adverse effects; risperidone dose reduction may be warranted when a potent CYP2D6 inhibitor is added |
| Carbamazepine and CYP3A4 Inducers (rifampin, phenytoin, St. John's Wort) | Strong CYP3A4 inducers substantially decrease risperidone and paliperidone plasma levels — carbamazepine can reduce risperidone exposure by approximately 50%. Risk of loss of antipsychotic efficacy and psychotic relapse. | High — risperidone dose may need adjustment when inducer is added or removed; monitor for return of psychotic symptoms |
| QT-Prolonging Drugs (methadone, fluoroquinolones, ondansetron, antiarrhythmics, TCAs, other antipsychotics) | Additive QTc prolongation raises risk of torsades de pointes ventricular arrhythmia. The risk is cumulative across all QT-prolonging agents in the patient's regimen. | Moderate-High — review total QTc burden; baseline and monitoring ECGs are warranted in high-risk patients |
| Dopamine Agonists (levodopa, pramipexole, ropinirole) | Pharmacodynamic antagonism — risperidone's D2 blockade counteracts the therapeutic benefit of dopamine agonists used for Parkinson's disease or restless legs syndrome. This interaction is bidirectional. | High — avoid risperidone in Parkinson's disease where possible; if antipsychotic is necessary, quetiapine or clozapine (with monitoring) are preferred due to lower D2 affinity |
| CNS Depressants (benzodiazepines, opioids, alcohol, sedatives) | Additive CNS and respiratory depression. Combination with parenteral benzodiazepines in the context of IM antipsychotic administration has been associated with rare fatalities. | Moderate — use with caution; monitor for excessive sedation and respiratory status when combining |
| Antihypertensives and Alpha-blockers | Additive hypotensive effects via risperidone's alpha-1 adrenergic blockade. Orthostatic hypotension and falls risk increases, particularly in elderly patients or those with baseline low blood pressure. | Moderate — monitor blood pressure; counsel patients to rise slowly from seated or lying positions |
| Lithium | Combined use may increase risk of neurotoxicity and extrapyramidal effects in some patients, though the combination is also intentionally used in bipolar disorder management. Requires monitoring rather than blanket avoidance. | Moderate — maintain lithium within therapeutic range; monitor for neurotoxicity signs |
Warnings & Contraindications
Contraindications
- Hypersensitivity to risperidone or paliperidone
- Use in elderly patients with dementia-related psychosis (black box warning — increased mortality risk)
Metabolic Monitoring Requirements
Risperidone, like all atypical antipsychotics, requires structured baseline and ongoing metabolic surveillance. Recommended assessments: body weight and BMI (baseline, monthly for 3 months, then quarterly), fasting blood glucose and HbA1c (baseline, 3 months, then annually), fasting lipid panel (baseline, 3 months, then annually), and blood pressure. Weight gain of more than 5% from baseline warrants re-evaluation and possible therapeutic intervention. Patients who develop hyperglycemia or significant dyslipidemia may need pharmacological management or consideration of a switch to a more metabolically neutral agent.
Hyperprolactinemia — Monitoring and Management
Risperidone produces clinically significant hyperprolactinemia more reliably and severely than other atypical antipsychotics. Sustained elevated prolactin causes gynecomastia and galactorrhea in men, menstrual disruption and infertility in women, and reduced bone mineral density — a concern particularly in younger patients on long-term therapy. Clinical symptoms of hyperprolactinemia should be assessed at each visit. In cases of symptomatic hyperprolactinemia, management options include: dose reduction, switching to a prolactin-sparing antipsychotic (aripiprazole, quetiapine), or augmentation with low-dose aripiprazole (which acts as a partial D2 agonist to normalize prolactin without sacrificing antipsychotic control).
Extrapyramidal Symptoms and Tardive Dyskinesia
Among atypical antipsychotics, risperidone carries a higher EPS burden than quetiapine, olanzapine, or clozapine, particularly above the minimum effective dose range. Clinicians should screen for EPS at every visit using structured assessments. Tardive dyskinesia can develop insidiously and may be masked by ongoing antipsychotic use. If TD is identified, options include: dose reduction, switch to a lower-D2 agent, or addition of a VMAT2 inhibitor (valbenazine or deutetrabenazine) specifically indicated for tardive dyskinesia management.
Pediatric Use
Risperidone is approved for pediatric schizophrenia (13+), bipolar mania (10+), and ASD-related irritability (5+). Children appear more susceptible to weight gain and metabolic effects. Prolactin elevation has particular implications during puberty and skeletal development. Regular monitoring of growth, weight, pubertal development, and metabolic parameters is essential. The long-term consequences of chronic antipsychotic use in developing brains require ongoing risk-benefit evaluation at each clinical encounter.
Check for QT prolongation risk or CYP2D6 interactions with risperidone.
Check Drug Interactions →Frequently Asked Questions
Why does risperidone cause elevated prolactin levels?
Risperidone blocks dopamine D2 receptors in the tuberoinfundibular dopamine pathway — the circuit that regulates prolactin secretion from the pituitary gland. Normally, dopamine suppresses prolactin release. When risperidone blocks D2 receptors in this pathway, that inhibitory brake is removed and prolactin levels rise substantially — often to levels 5–10 times the normal range. Unlike other atypical antipsychotics, risperidone has limited penetration into the pituitary-portal circulation relative to its brain entry, so it retains a strong prolactin-elevating effect even at lower doses. Elevated prolactin can cause menstrual irregularities, sexual dysfunction, galactorrhea (breast milk production outside of pregnancy), and long-term bone density loss.
Is risperidone still used for autism?
Yes. Risperidone was the first antipsychotic to receive FDA approval for irritability associated with autism spectrum disorder (ASD) in children ages 5–16, and remains one of only two medications approved for this purpose (the other being aripiprazole). It is not a treatment for autism itself — it does not improve social communication or core autistic features — but it reduces severe behavioral symptoms including self-injurious behavior, aggression, and tantrums. The decision to use risperidone in children requires careful risk-benefit assessment given its side effect profile, including weight gain, metabolic effects, and prolactin elevation in a pediatric population.
What is the difference between risperidone and paliperidone?
Paliperidone (Invega) is the active metabolite of risperidone. When the body metabolizes risperidone, it converts a large fraction to 9-hydroxyrisperidone, which is paliperidone. Both drugs have very similar pharmacological profiles — the same D2/5-HT2A antagonism — because paliperidone is, in effect, what risperidone becomes in the body. Paliperidone is available as a once-daily extended-release oral tablet and as long-acting injectables (Invega Sustenna monthly, Invega Trinza every three months). The main clinical difference is formulation convenience and the availability of very long-acting injectable versions that support adherence in chronic schizophrenia management.